Soft Tissue Sarcoma
Conditions
Keywords
sarcoma, ifosfamide
Brief summary
To study the activity and toxicity of a neoadjuvant regimen including high-dose ifosfamide in combination with radiotherapy, and subsequent surgery, in high-risk soft tissue sarcomas.
Detailed description
This is a phase II multicenter study designed in two phases. A total of 32 patients will be included in 10 hospitals belonging to the Spanish Group for Research in Sarcomas (GEIS). Selection criteria are: patients with localized soft tissue sarcoma from the extremities or trunk with high-risk features (\>5 cm and grade 2-3), or recurrences after prior inadequate surgery. The treatment schedule will be: initial biopsy, 3 cycles of high-dose Ifosfamide, 12 gr/m2 in 5 days, concurrent with Radiotherapy 50 Gy, and subsequent wide surgery. To assess the predictive factors of response to the combination therapy, DNA and RNA extraction will be performed on the pretreatment biopsies. DNA will be used to hybridize Affymetrix GeneChip® Human Mapping 500K Array, which allows for the study of 500000 SNPs throughout the genome. The expression of 39000 RNA transcripts will be evaluated employing the Affymetrix Genechip Human Genome HG-U133 Plus 2.0, and validated by real-time RT-PCR.
Interventions
DRUGIfosfamide
3 cycles of Ifosfamide (12g/m2) associated to Mesna (6g/m2), in i.v infusion 6 days, every 3 weeks
Sponsors
Grupo Espanol de Investigacion en Sarcomas
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Patients with Advanced Soft Tissue Sarcoma histological proven, potentially resected, located in extremities and trunk for one of the following histological subtypes: leiomyosarcoma, undifferentiated pleomorphic sarcoma, Synovial Sarcoma, Liposarcoma and malignant tumour of peripheral nerve sheath. 2. Primary tumour: 1. Size ³ 5 cm of diameter 2. Histological grade 2-3 3. Deep location 3. No distant metastases 4. Patients must have not been previously treated with Chemotherapy or Radiotherapy on the tumour area. 5. However patients are eligible with local relapse after previous surgery. 6. Patients must be £18 and ³ 65 years old. 7. Patients must have ECOG performance status 0 to 1 8. Patients must have measurable disease by Recist Criteria. 9. Absolute neutrophil count ³1,500/mm3, platelet count ³ 100,060 ml/min, creatinine, total bilirubin, ALT and AST £ 1.5 times the upper limit of normal 10. Signed informed consent prior to any study specific procedures
Exclusion criteria
1. Patients with cerebral metastasis 2. Pregnant or breast feeding patients. 3. Active infection or other concomitant severe illness. 4. Severe psychiatric illness which would not make possible the obtention of the informed consent 5. Concurrent treatment with other experimental drugs within 30 days prior to study entry. 6. History of previous treated or diagnosed cancer in the past 5 years, excepting basocellular cell skin cancer, cervix cancer in situ or superficial bladder carcinoma.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The efficacy of the neoadyuvant high-dose of ifosfamide and radiotherapy, determined with clinical and pathological responses | 10 weeks since the inclusion of the patient |
Secondary
| Measure | Time frame |
|---|---|
| Global survival, free relapse survival and toxicity | Until relapse or patient´s death |
Countries
Spain
Outcome results
None listed